Amphetamine
18 NDCs across 4 manufacturers|7 Generic,11 Brand
Amphetamine is used to treat attention deficit disorder with hyperactivity and narcolepsy, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jan 27, 2016, and the first generic was approved Jun 22, 2023. FDA's Orange Book lists 12 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $2 million on Amphetamine across 3,597 claims for 734 beneficiaries.
Amphetamine is available as 18 NDCs from 4 manufacturers (7 generic, 11 brand), with NADAC prices from $0.43 to $19.23 per EA — the most expensive product costs about 45× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Active FDA drug shortage
73 Amphetamine presentations are currently listed in FDA's drug shortage database (first posted Oct 12, 2022). Shortages can move NADAC prices in the following weeks.
Total NDCs
18
7G / 11B
Manufacturers
4
competing in market
Price Spread
$0.43 – $19.23
per EA, 17 of 18 NDCs
7d Activity
avg +0.6% WoW · of 18 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
4 manufacturers producing AMPHETAMINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ADZENYS XR-ODT 6.3 MG TABLET | $19.2313 per EA | +0.17% |
ADZENYS XR-ODT 3.1 MG TABLET | $19.2242 per EA | -0.18% |
ADZENYS XR-ODT 18.8 MG TABLET | $19.2202 per EA | -0.09% |
ADZENYS XR-ODT 12.5 MG TABLET | $19.2127 per EA | -0.05% |
ADZENYS XR-ODT 9.4 MG TABLET | $19.1952 per EA | +0.13% |
ADZENYS XR-ODT 15.7 MG TABLET | $19.1809 per EA | -0.05% |
AMPHETAMINE ER 12.5 MG ODT | $16.2480 per EA | -0.09% |
AMPHETAMINE ER 6.3 MG ODT | $16.2377 per EA | +0.04% |
AMPHETAMINE ER 9.4 MG ODT | $16.2264 per EA | -0.29% |
AMPHETAMINE ER 18.8 MG ODT | $16.2013 per EA | -0.80% |
AMPHETAMINE ER 15.7 MG ODT | $16.0418 per EA | +0.65% |
DYANAVEL XR 20 MG TABLET | $14.8279 per EA | +0.22% |
DYANAVEL XR 15 MG TABLET | $14.8016 per EA | -0.01% |
DYANAVEL XR 10 MG TABLET | $14.7880 per EA | -0.15% |
DYANAVEL XR 5 MG TABLET | $7.8501 per EA | -0.02% |
DYANAVEL XR 2.5 MG/ML SUSP | $2.7666 per ML | -0.02% |
AMPHETAMINE SULFATE 10 MG TAB | $0.4270 per EA | +2.60% |
AMPHETAMINE SULFATE 5 MG TAB | $0.4267 per EA | +7.76% |
Frequently Asked Questions
What is Amphetamine used to treat?
Amphetamine is used to treat attention deficit disorder with hyperactivity and narcolepsy, per the National Library of Medicine's MED-RT classification.
When did Amphetamine become available as a generic?
FDA approved the first generic Amphetamine (ANDA) on Jun 22, 2023. The Orange Book currently lists 12 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Amphetamine?
In 2024, Medicare Part D spent $2 million on Amphetamine across 3,597 claims for 734 beneficiaries.
Is Amphetamine in shortage?
Yes — FDA's drug shortage database currently lists 73 Amphetamine presentations with status "Current", first posted Oct 12, 2022.
How many Amphetamine products are on the market?
The Amphetamine drug market contains 18 NDCs from 4 manufacturers — 7 generic and 11 brand products.
What is the price range for Amphetamine?
NADAC reference prices for Amphetamine range from $0.4267 to $19.2313 per EA — the most expensive product costs about 45× the cheapest. 1 additional product is priced per a different unit (e.g. liquids per ML) and isn't directly comparable.
Is generic Amphetamine cheaper than brand?
The average generic NADAC for Amphetamine is $11.6870 per EA, versus $16.7532 for brand-labeled products — generic is about 30% cheaper on average.
Which manufacturers make Amphetamine?
4 manufacturers list Amphetamine in NADAC. Ranked by number of NDCs, the largest are Neos Therapeutics Brands, LLC (6), Teva Pharmaceuticals USA Inc. (5), NextWave Pharmaceuticals, Inc (5), Amneal Pharmaceuticals NY LLC (2).
How has the price of Amphetamine changed recently?
Over the past 7 days, 7 Amphetamine NDCs rose and 11 fell, with a market-wide average change of +0.6%.